Overcoming drug resistance with EAI-432, an allosteric EGFR inhibitor for non-small cell lung cancer
EAI-432, an allosteric inhibitor, offers a new approach to targeting mutant-EGFR driven NSCLC By binding outside the ATP pocket, it co-binds with the current standard-of-care third generation EGFR ...
Phase 1 clinical study to assess effect of cudetaxestat on pharmacokinetics of two approved therapies for idiopathic pulmonary fibrosis (IPF) Company on track to initiate planned phase 2 clinical ...
Colorectal cancer (CRC), a malignant tumor worldwide consists of microsatellite instability (MSI) and stable (MSS) phenotypes. Although SHP2 is a hopeful target for cancer therapy, its relationship ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (Blade or the Company), a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and ...
- ETX-636 advanced to the clinic following preclinical observations showcasing superior potency and selectivity for all mutant forms of PI3Kα while sparing wildtype PI3Kα Ensem Therapeutics, Inc.
AstraZeneca (NASDAQ:AZN) has entered into an exclusive option and global license deal with biotechnology company Allorion Therapeutics. The deal provides AstraZeneca (AZN) with an exclusive option to ...
Three studies of the human dopamine transporter reveal how it binds to molecules such as dopamine and cocaine. Dopamine imbalances underlie some brain conditions and these data will aid targeted drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback